[Serotonin syndrome and malignant neuroleptic syndrome. A review based on the material from the National Board of Adverse Drug Reactions].
The report describes four cases of serotonergic hyperstimulation classified as Serotonin Syndrome (SS) and 13 cases of supposed Neuroleptic Malignant Syndrome (NMS), all reported to the National Board of Adverse Drug Reactions. Diagnostic criteria, pathogenesis and some suspected risk factors are discussed. All patients with a diagnosis of "SS" were treated with more than one psychoactive drug, whereas five out of 13 NMS patients were treated with only one drug which could be suspected to be involved in the pathogenesis of the syndrome. Lithium seemed to be involved in three out of four SS cases and in one out of 13 cases of NMS. The syndrome occurred from less than an hour to several weeks after adding another drug to the patient's treatment. None of the cases of serotonergic hyperstimulation were severe enough to correspond to NMS and all patients recovered without sequelae, whereas at least three NMS patients died.
von Halling Laier
M G
MG
Sundhedsstyrelsens Bivirkningsnaevn, Brønshøj.
Gram
L F
LF
D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D000368:Aged; D003718:Denmark / Q000453:epidemiology; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000453:epidemiology*; D012701:Serotonin / Q000096:biosynthesis; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D013577:Syndrome
D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors